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(57) ABSTRACT 
A method for determining blood glucose levels by measur-
ing the glucose concentration in the ocular aqueous humor 
using optical refractometry by passing laser light the aque-
ous ocular humor, measuring the laser light's optical 
refractivity, and comparing the refractivity with known data, 
the comparison yielding the blood glucose level. 
17 Claims, 5 Drawing Sheets 
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NON-INVASIVE BLOOD GLUCOSE 
MEASUREMENT SYSTEM AND METHOD 
USING OPTICAL REFRACTOMETRY 
This application claims the benefit of U.S. provisional 5 
application No. 60,138,465 filed Jun. 10, 1999. 
FIELD OF THE INVENTION 
2 
as Affected by Insulin, Journal of Physiology, Vol. 156, pp. 
8-16 (1961); Pohoja, S., The Steady-State Ratio of Aqueous 
Glucose in Diabetic Hyperglycemia, Acta Ophthalmologica 
[Supp.], Vol. 88, pp. 51-54 (1966). In vivo measurements 
showed a steady-state ratio of blood plasma glucose levels 
to aqueous humor levels of 1.05 in rabbits, and a ratio of 
approximately 1.8 for the two human patients tested. Reim, 
M. et al., Steady State Levels of Glucose in the Different 
Layers of the Cornea, Aqueous Humor, Blood and Tears In 
The invention relates generally to the field of measuring 
the blood glucose levels of humans and, more specifically, to 
the field of measuring the blood glucose levels of humans 
using non-invasive techniques by measuring the optical 
refractivity of the ocular aqueous humor and comparing the 
measurements to known data. 
10 Vivo, Ophthalmologica, Vol. 154, pp. 39-50 (1967). This 
corresponds to a ratio of steady-state whole blood glucose 
concentration to aqueous ocular glucose concentration of 
approximately 1.6. Moreover, variations in blood glucose 
levels are reflected in corresponding variations in the con-
BACKGROUND OF THE INVENTION 
The potential for the non-invasive measurement of blood 
glucose concentration to improve the level of blood sugar 
control and the quality of life of diabetic patents has been 
recognized for nearly three decades. Cahill, G. F. et al, 
Practical Developments in Diabetes Research, Diabetes Vol. 
15 centration in the aqueous humor. Pohoja, S., The Glucose 
Content of the Aqueous Humor in Man, Dissertation, Uni-
versity of Helsinki (1966). 
In the nearly three decades since Cahill et al, supra, 
suggested that some property such as refractive index or 
20 near-infrared absorbance could be measured and correlated 
21 (Supp. 2), pp. 703-712 (1972). However, the ability to 
realize highly reliable and robust instrumentation capable of 
such measurements has continued to prove an elusive goal. 
The common thread among nearly all non-invasive tech-
25 
niques is the use of electromagnetic radiation to measure 
directly, or to infer indirectly, the blood glucose concentra-
tion. Numerous attempts have been made at non-invasive 
glucose measurement by directing electromagnetic radiation 30 
through the skin to measure blood glucose directly. 
with glucose level, a wide range of optical techniques have 
been promoted for determination of the glucose concentra-
tion in the aqueous humor. In U.S. Pat. No. 3,958,560 to 
March, use of a contact lens with an integrated infrared 
source, such as zirconium-filament light bulb, and a detector 
which would measure the amount of energy transmitted 
transversally through the cornea anterior to the iris and pupil 
is disclosed. In such a system, the enhanced absorption from 
the hydroxyl portion of the glucose molecule was thought to 
be measurable, and would be directly proportional to glu-
cose abundance. March '560 also suggested that visible light 
might be introduced on the same transversal path and 
detected by an interferometer, which would measure the 
change in refractive index due to the refraction from glucose 
35 in the aqueous humor. The change in refractive index would 
likewise be proportional to glucose concentration in the 
aqueous humor. Unfortunately, neither effect was shown to 
be measurable using the technological approaches of the 
1970's. 
The most promising direct measurement approaches 
transmit radiation in the near infrared portion of the elec-
tromagnetic spectrum through the skin and estimate glucose 
concentration from the spectral signature of the absorption at 
selected wavelengths from 1-3 microns. In the 1-3 micron 
range, the absorption spectrum from water is not as domi-
nant as at longer wavelengths, and there exist a number of 
unique, detectable features in the glucose absorption spec-
trum. Arnold, M. A, Handbook of Clinical Laboratory 40 
Automation, Robotics and Optimization, Chapter 26 (ed. 
Kost), John Wiley & Sons, New York (1996); Burmeister, J. 
J. et al., Spectroscopic Considerations for Noninvasive 
Blood Glucose Measurements with Near Infrared 
Spectroscopy, IEEE LEOS Newsletter, Vol. 12, pp. 6-9 45 
(1998). However, transdermal measurements are especially 
challenging given the variability in path length from mea-
surement to measurement, and given the spectral complexity 
of the fatty tissue and the myriad of constituents contained 
in biofiuids such as whole blood. Approaches for correcting 50 
for such effects are discussed by Burmeister and Arnold. 
As an alternative, the ocular aqueous humor (in the 
anterior portion of the eye) contains far fewer constituents 
that would interfere with the spectroscopic detection of 
glucose. Lambert, J. et al., Measurement of Physiologic 55 
Glucose Levels Using Raman Spectroscopy in a Rabbit 
Aqueous Humor Model, IEEE LEOS Newsletter, Vol. 12, 
pp. 19-22 (1998); Wicksted, J.P. et al., Raman Spectroscopy 
Studies of Metabolic Concentrations in Aqueous Solutions 
and Aqueous Humor Specimens, Applied Spectroscopy, Vol. 60 
49, pp. 987-993 (1995). Likewise, if the eye position can be 
held stable relative to the sensor, the path length through the 
anterior portions of the eye is quite stable. 
Throughout the 1950's and 60's, a number of studies of 
the relationship between blood glucose levels and glucose 65 
levels in the aqueous humor were conducted. Kinsey, V. E. 
et al., Transport of Glucose Across Blood-Aqueous Barriers 
As an alternative, in U.S. Pat. No. 4,014,321 to March, a 
system which radiated polarized light on the transversal path 
through the cornea and then measured the change in polar-
ization upon exit could be used to infer the glucose concen-
tration in the aqueous humor since glucose is optically active 
is disclosed. This was especially attractive, since the major-
ity of laser energy would not be directed toward the retina. 
The safe retinal exposure level for pulsed lasers in the near 
IR is on the order of 1-10 millijoules depending on pulse 
duration, with an exposure power limit of approximately to 
microwatts for continuous wave (CW) exposure. FDA Stan-
dards for Laser Safety, 21 C.F.R. Sec. 1040; Tarr, R. V. et al., 
The Non-Invasive Measure of D-Glucose in the Ocular 
Aqueous Humor using Stimulated Raman Spectroscopy, 
IEEE LEOS Newsletter, Vol. 12, pp. 22-27 (1998). 
The use of optical polarimetry for measurement of ocular 
glucose has been a dynamic area of research of the past two 
decades. Results were reported from tests of an optical 
bench model of a polarimetric glucose sensor in which 
glucose concentrations as low 20 mg/dl were measured in a 
test cell. Rabinovitch, B. et al., Noninvasive Glucose Moni-
toring of the Aqueous Humor of the Eye: Part I. Measure-
ment of Very Small Optical Rotations, Diabetes Care, Vol. 
5, pp. 254--258 (1982). This corresponded to optical rota-
tions of about only 40 arcseconds. The same optical bench 
model was used to measure glucose concentrations of rabbit 
ocular aqueous humor which was removed by paracentesis 
directly into a test cell. March, W. F. et al., Noninvasive 
US 6,442,410 Bl 
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Glucose Monitoring of the Aqueous humor of the Eye: Part 
II. Animal Studies and the Scleral Lens, Diabetes Care, Vol. 
5, pp. 259-265 (1982). Work on an experimental scleral lens 
was also described in this study for non-invasive measure-
ment of glucose concentrations in the aqueous humor of test 5 
animals, but the optical activity of constituents other than 
glucose, plus the birefringence of the cornea, made it 
extremely difficult to unambiguously infer the glucose con-
centration in the aqueous humor of the test animals. 
In an attempt to correct for these problems, a multi- 10 
wavelength polarimeter, which has the potential to detect 
possible wavelength dependencies in the optical activity, 
which could then make it possible to separate the effects of 
the different constituents and to correct for birefringence in 
the cornea has been suggested. McNichols, R. J. et al., 15 
Development of a Non-Invasive Polarimetric Glucose 
Sensor, IEEE LEOS Newsletter, Vol. 12, pp. 30-31 (1998); 
Cote, G. L., Diabetes Technology and Therapeutics, Vol. 1 
(1999). The addition of optical modulators to this polarim-
eter also increases its sensitivity over that previously 20 
achieved. A higher sensitivity polarimeter has been sug-
gested by placing the glucose samples (and in an eventual 
operational system, presumably the eye) under a moderate 
magnetic field, so as to enhance the polarization rotation due 
to glucose. Jang, S. et al., Optical Sensor using the Magnetic 25 
Optical Rotatory Effect of Glucose, IEEE LEOS Newsletter, 
Vol. 12, pp. 28-30 (1998). 
4 
Using the more traditional spontaneous Raman spectro-
scopic technique, successful measurements of the concen-
tration of glucose in a simulated rabbit aqueous humor have 
been made. Lambert, J. et al., Measurement of Physiologic 
Glucose Levels Using Raman Spectroscopy in a Rabbit 
Aqueous Humor Model, IEEE LEOS Newsletter, Vol. 12, 
pp. 19-22 (1998); Lambert, J., Diabetes Technology and 
Therapeutics, Vol. 1 (1999). Likewise in-vitro measure-
ments of the glucose concentration in rabbit aqueous humor 
samples have been made. Id. While the stimulated Raman 
technique is often more sensitive since the interference from 
protein fluorescence is not present, this spontaneous Raman 
spectroscopic technique can achieve high sensitivity through 
the incorporation of high-level spectral retrieval techniques 
to infer glucose concentration based on the entire measured 
Raman spectrum, rather than just a few key Raman frequen-
cies. Sensitivities better than 50 mg/dl have been made when 
measuring simulated rabbit aqueous humor. Lambert, J. et 
al., Measurement of Physiologic Glucose Levels Using 
Raman Spectroscopy in a Rabbit Aqueous Humor Model, 
IEEE LEOS Newsletter, Vol. 12, pp. 19-22 (1998). Even 
though spontaneous Raman systems require direct frontal 
illumination of the aqueous humor to obtain detectable 
scattering from glucose, focusing occurs within the cornea, 
which both (beneficially) increases the power density in 
aqueous humor, and reduces the power density in the vicin-
ity of the retina. Lambert, J., Diabetes Technology and 
Therapeutics, Vol. 1 (1999). 
To date, none of these methods has proven to have the 
reliability, accuracy and ease of use which would optimally 
Another approach to the unambiguous measurement of 
the glucose concentration in the aqueous ocular humor is the 
use of spectroscopic techniques. U.S. Pat. No. 5,243,983 to 
Tarr and Steffes discloses the use of stimulated Raman 
spectroscopy for such measurements, since the cost of 
components was low, and since glucose-specific features of 
the Raman spectrum in the aqueous humor could be iden-
tified and measured with such a system. Tarr, R. V. et al., The 
Non-Invasive Blood Glucose Measure of D-Glucose in the 
Ocular Aqueous Humor using Stimulated Raman 
Spectroscopy, IEEE LEOS Newsletter, Vol. 12, pp. 22-27 
(1998). In a stimulated Raman system, two laser waves 
whose frequencies are separated by a Raman resonance 
frequency specific to glucose traverse a medium, and the 
amount of energy which is transferred from one beam to the 
other (through stimulated Raman scattering) is measured 
and related to the abundance of glucose. 
30 be desirable to produce a workable device for everyday patient use. Clearly, there is a need for an improved non-
invasive method for obtaining an approximation of a 
patient's blood glucose level which has increased reliability, 
accuracy and ease of use. 
The spectral nature of the aqueous ocular fluids allows 
Raman spectroscopy to be highly effective for identifying 
the concentration of constituent abundances, including glu-
cose. Erckens, R. J. et al., Raman Spectroscopy for Nonin-
vasive Characterization of Ocular Tissue-Potential for 
Detection of Biological Molecules, Journal of Raman 
Spectroscopy, Vol. 28, pp. 293-299 (1997). One feature of a 
system employing stimulated Raman spectroscopy is its use 
of the same transversal path used in the polarimetric systems 
discussed above. This provides a much lower level of retinal 
exposure, and allows measurements of glucose concentra-
tions at the level of 0.5% (by weight) using low-cost, 
low-power, solid-state lasers. Tarr, R. V. et al., The Non-
invasive Blood Glucose Measure of D-Glucose in the Ocu-
Accordingly, it is an object of the present invention to 
35 provide a process for measuring the blood glucose levels of 
humans using a non-invasive technique which is convenient 
and easy to use by patients on their own. 
Furthermore, it is an object of the present invention to 
provide a process for measuring the blood glucose levels of 
40 humans which is not subject to path length variability and is 
thus more accurate than conventional non-invasive methods. 
It is yet another object of the present invention to provide 
a method for measuring the blood glucose levels of humans 
based upon their ocular refractivity which minimizes the 
45 
exposure of the retina to potentially damaging power levels 
of electromagnetic radiation. 
BRIEF DESCRIPTION OF THE INVENTION 
The above objectives are accomplished according to the 
50 present invention by providing a process and method for the 
non-invasive determination of a mammal's, preferably a 
human patient's, blood glucose level by measuring the 
required refractive correction of the mammal's eyes. More 
specifically, the method of the present invention includes the 
55 steps of measuring the mammal's required refractive cor-
rection and correlating the measured required refractive 
correction to the mammal's blood glucose level using a 
previously determined relationship between the mammal's 
lar Aqueous Humor using Stimulated Raman Spectroscopy, 
IEEE LEOS Newsletter, Vol. 12, pp. 22-27 (1998). Since the 60 
sensitivity of stimulated Raman systems is related to the 
power and stability of the lasers used, and to the spatial 
compactness of the laser beams, use of higher stability, 
higher power semiconductor lasers with more compact and 
uniform spatial beamwidths could make possible measure- 65 
ments at the 0.01 % level over paths comparable to that 
required refractive correction at a known blood glucose 
concentration. 
Other objects, aspects, and advantages of the present 
invention will be apparent to those skilled in the art from a 
reading of the following detailed disclosure of the invention. 
BRIEF DESCRIPTION OF THE FIGURES 
The construction and design to carry out the invention 
will hereinafter be described together with other features through the cornea. 
US 6,442,410 Bl 
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thereof. The invention will be more readily understood from 
a reading of the following specification and by reference to 
the accompanying drawings forming a part thereof, wherein 
an example of the invention is shown and wherein: 
FIG. 1 is a block diagram illustrating a preferred embodi-
ment of the method of the present invention. 
FIG. 2 is perspective view of a portable refractometer and 
calculator in accordance with a preferred embodiment of the 
present invention. 
FIG. 3 is a schematic diagram illustrating Gullstrand's 
Model of the eye. 
FIG. 4 is a schematic illustrating the Paraxial Ray Tracing 
technique used in the theoretical calculation of refractive 
parameters. 
FIG. SA is a comparison of finger-stick measurements of 
whole blood glucose taken with One-Touch brand system 
(circles) and Fast-Take brand system (squares). 
FIG. SB is the measured required optical refractive cor-
rection for a test patient during induced hypoglycemia. 
FIG. 6 is a graph of the data of Example 2 illustrating the 
correlation of blood glucose level with required refractive 
correction. 
DETAILED DESCRIPTION OF IBE 
PREFERRED EMBODIMENT 
6 
patient's eye matches a certain image in the database des-
ignated as correct vision, this determines the required refrac-
tive correction. One of ordinary skill in the art will recognize 
that any of the known or yet to be discovered methods of 
5 determining the required refractive correction are suitable 
for use in the present invention. 
The aqueous humor 16 has a certain refractive index. This 
refractive index varies with the blood glucose concentration. 
Under normal circumstances, the light rays 12 pass through 
10 the aqueous humor 16 and are refracted a certain amount. 
When the blood glucose concentration changes, the refrac-
tive index of the aqueous humor 16 changes, thus refracting 
the light rays 12 to a different path 12A. This causes the light 
rays 12A to focus at a different point, such as point F'. The 
15 difference between point F and point F' is measurable by a 
refraction measurement device 24. This difference is com-
pared to a known database of correlative values, and the new 
blood glucose concentration can be determined. 
In one preferred embodiment refraction measurement 
20 device 24 uses laser light as the light rays 12 to determine 
the current optical refractivity of the aqueous humor and 
compare it to a baseline measurement of the aqueous humor. 
The difference between the current optical refractivity and 
the baseline refractivity is indicative of the change in the 
25 blood glucose concentration of the patient, and the current 
blood glucose concentration of the patient can be determined 
without invasion into the body. Referring now in more detail to the drawings, the inven-
tion will now be described in detail. As shown in FIG. 1, the 
present invention involves the use of a means for measuring 30 
the required refractive correction of a mammal's eyes and 
the correlation of the measured refractive correction to the 
blood glucose level of the mammal. The preferred mammal 
The general method for determining the glucose concen-
tration is to compare the current required refractive correc-
tion necessary in the patient to the known required refractive 
correction of the patient at a known blood glucose 
concentration, and to compare the difference between the 
two to a known database of correlative differences. For is a human patient which will be referred to simply as the 
patient. The general method for determining the glucose 35 
concentration is to compare the current required refractive 
correction necessary in the patient to the known required 
refractive correction of a patient who has a known blood 
glucose concentration, and to compare the difference 
between the two to a known database of differences, inter- 40 
polating to determine the patient's blood glucose concen-
tration. 
example, a patient has a known required refractive correc-
tion of 3.25 diopters and a known blood glucose concentra-
tion of 95 mg/dl. The current required refractive correction 
for the patient is determined by any of the known methods 
to be 3.75 diopters. The difference of 0.50 diopters is 
compared to a known database, and the current blood 
glucose concentration is interpolated. 
The database with the relationship among the known 
refractive correction, the known blood glucose 
concentration, the current required refractive correction, and 
Atypical eyeball 10 is shown in FIG. 1. Light rays 12 pass 
through the cornea 14, the aqueous humor 16, and the lens 
18. For eyes that do not need correction, and for eyes that 
have proper correction (eyeglasses, contact lenses, correc-
tive surgery or the like), the light rays 12 focus on the retina 
20 at point F. For eyes that need correction and are not 
corrected, the light rays 12 do not focus on the retina 20, but 
either focus at a point inside the interior 22 of the eyeball 10, 
or at a theoretical point outside of the eyeball 10. This new 
point can be measured using a measurement device, such as 
refraction measurement device 24. 
45 the current blood glucose concentration can be developed 
without undue experimentation by one of ordinary skill in 
the art. For example, one method would be to measure the 
normal required refractive correction and the normal blood 
glucose concentration of a patient, induce a change in the 
50 blood glucose concentration of the patient by artificial 
means (fasting or ingestion of high-glucose foods or 
liquids), and measuring the current required refractive cor-
rection and the current blood glucose concentration of the 
patient after a predetermined time period from the onset of For example and not limitation, refraction measurement 
device 24 may be a traditional lens set or an automatic 
refractometer. Traditional lens sets are used in conjunction 
with charts, such as the well-known chart with letters 
descending in size from the top of the chart to the bottom of 
the chart. The patient views the chart through the lens set, 
and various different lenses are placed in front of the 60 
patient's eyes. When the patient is able to comfortably read 
certain lines of the chart, the practitioner notes which lens 
was used, and this determines the required refractive cor-
rection. Automatic refractometers work by projecting an 
image on the back of the patient's eye and comparing the 65 
image on the back of the patient's eye (on the retina) with 
a computer database. When the image on the back of the 
55 the artificial means of altering the blood glucose concentra-
tion of the patient. A more detailed examination of the 
relationship between measured refractive correction and 
blood glucose levels will be presented below in the Theo-
retical Analysis section. 
In an envisioned preferable embodiment, the refractive 
correction necessary for the patient's eye will be measured 
using a small handheld automatic refractor 30 about the size 
of a binocular, as shown in FIG. 2. One end of the device 
will have a cup-like aperture 32 that will fit onto the patient's 
eyes 10 (left or right). The cup-like aperture 32 is designed 
to prevent the external light sources (light, electrical outlets, 
electrical appliances) from interfering with accurate mea-
US 6,442,410 Bl 
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surements. It is envisioned that the automatic refractor 30 
will communicate with a handheld microprocessor 34 which 
will display a numerical blood glucose value (mg/dl) to the 
patient on an LCD display 36. 
Theoretical Analysis 5 
To implement the method of the present invention, we 
first determined the relationship between blood glucose level 
and the refractive index of the eye. The relationship between 
D-glucose concentration, refractive index, and aqueous 
solution was calculated. The Gullstrand's theoretical model 10 
was used (see FIG. 3). From this figure, collection of 
following data is obtained: the radius of cornea 14, lens 18 
and vitreous body. Utilizing the already established ratio of 
1.8 (glucose concentration in blood to the concentration of 
glucose in aqueous humor 16), calculation for the changes in 15 
refractive indices of aqueous humor 16 is shown in the 
following section (also refer to Table 1). 
TABLE 1 
8 
by a factor of 1.8. Using this information, equation (2) was 
generated. 
R'~3. 684*10-6 *G'+ 1.3357953 (2) 
R' is the refractive index in the aqueous humor 16. The 
variable G' is the glucose concentration in the eye 10. 
Equations (1) and (2) were used as a basis for the theoretical 
calculations. 
Two different approaches were used to obtain the neces-
sary data for the theoretical calculations. First, graphical 
analysis was used. The magnitude of the modeled eye 10 
was enlarged by factor of 20. Next, the curvature of cornea 
14 and the lens 18 (found in the Gullstrand's model and 
Snell's law) was used to trace the light ray. However, the 
hand ray tracing calculations were not accurate in that, for 
a person with a perfect vision, the graph showed an approxi-
mate error of six diopters. 
Thickness 20 Therefore, it was necessary to utilize a second method, 
Cornea 
Aqueous Humor 
Lens 
Vitreous Humor 
Radius 
Cornea 
Anterior Lens Surface 
Posterior Lens Surface 
Refractive Index 
Cornea 
Aqueous Humor 
Lens 
Vitreous Humor 
0.527 mm 
3.07 mm 
3.6 mm 
16.97 mm 
7.8 mm 
10 mm 
-6 mm 
1.376 
Various 
1.413 
1.336 
tk 
nk 
Paraxial Ray Tracing, to perform the calculations. Paraxial 
Ray Tracing is accomplished by tracing the path of a light 
ray with very small units (mm were used). The Paraxial Ray 
Tracing method satisfied the design requirements. FIG. 4 is 
25 a graphical explanation of the paraxial ray tracing. In this 
figure, y is the ray height at the surface. The variable u is the 
slope angle, and t is the distance between two surfaces. The 
last variable R is the radius of the surface. A diameter of 30 
mm was assumed as the incident ray to the eye. Through this 
30 assumption, beginning value of y=15 mm was obtained (also 
assuming a infinite ray source). Table 2 summarizes the 
results of the mathematical calculations obtained through 
this example. Table 2 was generated for a patient having a 
blood glucose concentration within the normal range (72 
mg/dl). 
TABLE 2 
0.529 3.07 3.6 16.89 
1.376 1.336 1.413 1.336 
ck 0 1/7.8 1/7.8 1/10 -1/6 
Yk 1.5 1.5 
nuk 0 
Uk 0 
First, a table containing the properties of D-glucose in 
aqueous solution was used to find refractive index change 
with different glucose concentration in the eye 10. The 
content composition of aqueous humor 16 (in the human 50 
eye) is more complex than pure aqueous solution. Assuming 
that the glucose concentration (given in the sample calcu-
lation of the Gullstrand's model) is at 100 mg/di, a value of 
1.3335795333 was calculated. Given the slope of the linear 
equation (3.684A -6), and the value of the y-intercept, equa- 55 
tion (1) was generated. 
R~3.684*10-6*G+ 1.33366 (1) 
1.4722 1.323 1.323 0 
-0.0723 -0.0648 -0.0750 -0.0895 
-0.0525 -0.0485 -0.0531 -0.0670 
Application of these equations yields the following 
results. For the person with normal blood glucose concen-
tration (calculation shown in Table 2), the focal point is 
16.89 mm behind the posterior of the lens. This implies that 
the distance between the focal point and the retina 20 is -5.3 
µm. This is equal to a refractive correction reading of -0.19 
diopters. This is very close to perfect vision. Next, another 
calculation with glucose concentration of 180 mg/dl was 
performed. Through this calculation, the result of -0.26 
diopters was obtained. Using equation (3) with two calcu-
lated parameters, blood glucose level was determined. 
GC~-1408. 72 *D-195.65 (3) 
60 The variable GC is the glucose concentration in blood, 
R is the refractive index. The variable G is the glucose 
concentration in aqueous solution. Thus, equation (1) sets 
forth the relationship between the refractive index and 
concentration of glucose in eye. 
Next, the concentration of glucose in the aqueous humor 
16 was obtained by dividing the blood glucose concentration 
and D is the refractive correction. The slope of equation (3) 
is should remain constant from person to person. The slope 
is the relationship between glucose concentration and diopt-
ers. The constant (195.65) in the equation (3) will vary from 
65 person to person. This constant can vary due to factors such 
as the condition of the patient's eye (nearsighted or 
farsighted), age, and/or astigmatism. The subject used in 
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Example 1 was nearsighted. In comparing the theoretical 
versus the experiment results, the analysis need only rely 
upon the changes in the relative slope of the two equations. 
EXAMPLE 1 
Of major concern in measurement of ocular glucose for 
determining plasma glucose levels is the potential for delays 
5 
10 
nique can also be combined with refractive index measure-
ment. 
EXAMPLE 2 
The utility of the present invention was demonstrated 
using a (Type 1) diabetic patient as a test subject. As a 
control, the patient used a plasma-calibrated blood glucose 
meter (FastTake™ brand) to determine his blood glucose in 
in changes in the ocular glucose concentration relative to 
changes in the plasma glucose (i.e., latency). Kinsey, V. E. 
et al., Transport of Glucose Across Blood-Aqueous Barriers 
as Affected by Insulin, Journal of Physiology, Vol. 156, pp. 
8-16 (1961); DiMattio, J., Decreased Ascorbic Acid Entry 
into Cornea of Streptozotocin-Diabetic Rats and Guinea 
Pigs, Exp. Eye Res., Vol. 55, pp. 337-344 (1992). The 
dynamic relationship between ocular glucose and plasma 
glucose has shown to be rapid in rabbits and in rats, but time 
constants for glucose equilibration in humans have not been 
determined. 
10 
the plasma portion of his blood. This means that the red 
blood cells are removed before the meter determines the 
blood glucose level. The refraction portion of the testing 
procedure utilized a Reichert Ophthalmic Instruments 
Model AR350 auto refractor, which is affordable, easy to 
operate, and has a high resolution (0.01 D). 
15 
Shortly after the blood glucose meter reading (within a 5 
minute period), the patient used the AR350 auto refractor to 
determine his refractive correction in diopters. The auto 
re fr actor was preset to take five measurements in one sitting. 
To provide some indication of the rapidity of this 
equilibration, a demonstration was conducted involving a 
well-controlled IDDM patient (Hb-Alc<6%) regulated with 20 For every blood glucose reading, there were five measure-
ments taken. an insulin pump. As shown in FIG. SA, a baseline whole-
blood glucose level of approximately 95 mg/dl was main-
tained in the fasting patient using an insulin pump admin-
istering 0.5 units/hr of Lispro insulin analog. Hypoglycemia 
was induced with a bolus administration of 3 units Lispro. 25 
Concurrent measurement of refractive effects of ocular 
glucose on the patient's required refractive correction were 
made by a practitioner using both a Humphries brand 
auto-refractor and a traditional lens set. 
During the course of testing it became apparent that 
elimination of ambient room lighting could significantly 
improve the accuracy of the refractivity measurements. In 
fact, no significant correlation was observed between blood 
glucose levels and refractive correction at high levels of 
ambient light. Accordingly, the refractivity measurements 
should be carried out under conditions having minimal 
ambient light or using apparatus which shields ambient light 
30 away from the patient's eye. This function is provided by the 
use of a cup like aperture 32 through which the patient looks, 
as illustrated in FIG. 2 
As shown in FIG. SB, the patient's mean correction 
(average of both eyes), which was stable at 5.375 diopters 
previous to the experiment decreased measurably (0.25 
diopters) upon induction of hypoglycemia with minimal 
delay. Its return to the previous stable value tracked that of 
the digital capillary blood glucose measured using two 35 
different meters nearly instantaneously. Obviously, constitu-
ents other than glucose have effect on the refractivity of the 
aqueous humor. However, on a short-term basis, the vari-
ability of these constituents is relatively small in an 
otherwise-healthy patient. Thus, such a refractivity measure- 40 
ment can accurately reflect short-term variations of ocular 
glucose. 
A total of twelve glucose readings were taken with the 
glucose meter. For each blood glucose reading, five auto 
refractor measurements were take. A total of sixty data pairs 
were obtained. Of the auto refractor measurements taken 
(for each trial), the highest and the lowest values were 
discarded. For each glucose reading, the remaining three 
auto refractor measurements were recorded for a total of 
thirty-six data pairs shown in Table 3. The x-value is the 
blood glucose level and the y-value is the corresponding 
refractive correction determined by the auto refractor. 
TABLE 3 
Data From Testing 
Test: 2 3 4 5 7 8 9 10 11 12 13 14 15 16 17 18 
x: 42 42 42 50 50 50 61 61 61 61 61 61 98 98 98 168 168 168 
y: -4.92 -4.94 -5.04 -5.01 -5.09 -5.07 -5.04 -4.97 -4.99 -5.09 -5.14 -5.11 -4.84 -4.91 -4.98 -4.91 -5 -5.2 
Test: 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 
x: 183 183 183 185 185 185 198 198 198 213 213 213 234 234 234 276 276 276 
y: -5.04 -5.04 -5.35 -5.15 -5.2 -5.2 -5 -5.02 -5.16 -4.92 -5.04 -5.17 -4.99 -5.12 -5.32 -5.39 -5.09 -5.38 
Such a demonstration shows the utility of an instrument 
which measures ocular glucose in the treatment and control 
FIG. 6 is a graphical display of the data in Table 3. A trend 
line shows that, as blood glucose increases, the patient 
60 becomes more nearsighted. Equation (4), of diabetes. Based on the relative spectral simplicity of the 
aqueous humor, and the rapidity with which variations in its 
glucose concentration mirrors that in the blood, laser-based 
measurement of glucose concentration in the aqueous humor 
can be used in a system for non-invasive determination of 
blood glucose levels. Either multi-wavelength polarimetry 65 
or Raman spectroscopy can yield a useful instrument for 
both clinical use and patient self-monitoring. Either tech-
y~-284.04x-1295.1 (4) 
also shown in the FIG. 6, is the calibrated equation for the 
patient who was tested (each patient will have his/her own 
calibration equation). The calibrated equation for each indi-
vidual should display similar trends. 
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The correlation between refractive correction and blood 
glucose was calculated using equation (5). 
~ (x; - x)(y; - Y) 
r = ---;=====-;==== ~ 2.: (x; - x) 2 ~ 2.: (y; - yJ2 
(5) 
where 
5 
(6) 10 
s = "\' y2 - (~ yf 
yy L....J I ll 
(7) 
15 
(8) 
12 
sured ocular refractive correction in relation to a plurality of 
data from said database. 
8. The method of claim 2, wherein said measuring step 
includes the step of shielding an eye from external light. 
9. An apparatus for determining a mammal's blood glu-
cose level, said apparatus comprising: 
a refractometer for measuring ocular refractive correction, 
said refractometer outputting data indicative of the 
ocular refractive correction; and 
a processor adapted to receive said data indicative of the 
ocular refractive correction from said refractometer, 
said processor being operative to correlate said data to 
a correlated blood glucose level, said processor output-
ting a signal indicative of said correlated blood glucose 
level. 
10. The apparatus of claim 9, wherein the mammal is a 
human. 
Pearson's sample correlation r=-0.48867 and an r2 =0.2389 
was generated. This r-value does imply that there is a weak 
correlation. A perfect linear relationship would be r=( +/-)1. 
20 
11. The apparatus of claim 10, further comprising a 
display adapted to display the correlated blood glucose 
level. 
From the result of the theoretical calculations, the rela-
tionship between the glucose concentration and the refrac-
tive correction had a slope of -1408.72. The experimental 25 
slope is -284.04. Percent error in this case (of the two 
slopes) is [ 1-( experimental/theoretical)]= 79 .83 % . 
Nonetheless, the relationship between glucose concentration 
of the eye and blood glucose is visible, demonstrating the 
utility of this technique. 30 
12. A method for determining blood glucose concentra-
tions based on ocular refractive correction, said method 
comprising the steps of: 
measuring the ocular refractive correction needed to cor-
rect a mammal's vision; and 
comparing the ocular refractive correction with predeter-
mined ocular refractive corrections correlated to pre-
determined blood glucose concentrations. 
13. The method of claim 12, wherein the ocular refractive 
correction is measured with an automatic refractometer. 
14. The method of claim 13, wherein the mammal is 
It, thus, will be appreciated that the objects of this 
invention have been fully and effectively accomplished. It 
will be realized, however, that the foregoing preferred 
specific embodiment has been shown and described for the 
purpose of this invention and is subject to change without 
departure from such principles. Therefore, this invention 
includes all modifications encompassed within the spirit and 
scope of the following claims. 
35 human. 
What is claimed is: 
1. A method for determining a mammal's blood glucose 
level based on ocular refractive correction, said method 40 
comprising the steps of: 
measuring the ocular refractive correction of the mammal; 
relating the measured ocular refractive correction of the 
mammal to the mammal's blood glucose level by 45 
comparing the measured ocular refractive correction to 
a database of known ocular refractive corrections and 
blood glucose concentrations. 
2. The method of claim 1, wherein the mammal is a 
human. 50 
3. The method of claim 2, including the further steps of: 
measuring the ocular refractive correction at least a sec-
ond time; and 
averaging the measured ocular refractive corrections to 
obtain a value. 
4. The method of claim 2, wherein said step of measuring 
the ocular refractive correction is performed using a tradi-
tional lens set. 
55 
5. The method of claim 2, wherein said step of measuring 
the ocular refractive correction is performed using an auto- 60 
matic refractometer. 
6. The method of claim 2, further including the initial step 
of measuring the ocular refractive correction at a plurality of 
known blood glucose levels. 
7. The method of claim 2, further including the step of 
interpolating a blood glucose value correlated to the mea-
15. The method of claim 12, wherein the ocular refractive 
correction is measured in diopters. 
16. A method of monitoring changes in blood glucose 
concentration, said method comprising the steps of: 
calibrating a patient's blood glucose concentration with 
the patient's ocular refractive correction; 
measuring the patient's ocular refractive correction; and 
interpolating the patient's blood glucose concentration 
based on the calibration. 
17. A method of monitoring changes in blood glucose 
concentration, said method comprising the steps of: 
taking a first ocular refractive correction measurement of 
a patient; 
taking a first blood glucose concentration measurement 
from the patient; 
taking a second ocular refractive correction measurement 
and a second blood glucose measurement from the 
patient after inducing a change in the patient's blood 
glucose concentration; 
correlating the ocular refractive correction measurements 
with the corresponding blood glucose concentrations; 
taking a third ocular refractive correction measurement of 
the patient; and 
interpolating the blood glucose concentration correspond-
ing to the third ocular refractive correction measure-
ment. 
* * * * * 
